The discovery that a single DNA repair enzyme can either help or hinder viral infections depending on the pathogen reveals new therapeutic vulnerabilities in retroviral diseases. This finding challenges the assumption that cellular repair mechanisms uniformly protect against viral hijacking. RAD51, the central enzyme in homologous recombination DNA repair, demonstrates dramatically different responses to HIV-1 versus HTLV-1 infections. HIV-1 viral proteins Tat and Vpr actively boost RAD51 expression, creating a cellular environment that enhances both DNA repair fidelity and viral gene transcription through NF-κB pathway interactions. This elevation supports HIV's strategy of persistent infection while maintaining host cell viability. HTLV-1 employs the opposite approach, using viral proteins p30 and Tax to suppress RAD51-mediated repair, deliberately steering cells toward error-prone DNA repair pathways that accumulate mutations and drive oncogenic transformation. This mechanistic insight connects HTLV-1's cancer-causing potential directly to its interference with genome maintenance systems. The contrasting viral strategies suggest RAD51 functions as both a potential antiviral restriction factor and a co-opted replication enhancer, depending on evolutionary pressures faced by each retrovirus. These opposing mechanisms open therapeutic possibilities, particularly combining RAD51 modulators with PARP inhibitors to exploit synthetic lethality in HTLV-1-associated adult T-cell leukemia. The research represents a significant advance in understanding how retroviruses manipulate fundamental cellular processes, potentially explaining why different retroviruses cause such distinct disease patterns despite similar replication strategies.